CH716073B1 - Retard-Mischlösung zur Etablierung eines Endometriose-Mausmodells und deren Herstellungsverfahren. - Google Patents
Retard-Mischlösung zur Etablierung eines Endometriose-Mausmodells und deren Herstellungsverfahren. Download PDFInfo
- Publication number
- CH716073B1 CH716073B1 CH01157/20A CH11572020A CH716073B1 CH 716073 B1 CH716073 B1 CH 716073B1 CH 01157/20 A CH01157/20 A CH 01157/20A CH 11572020 A CH11572020 A CH 11572020A CH 716073 B1 CH716073 B1 CH 716073B1
- Authority
- CH
- Switzerland
- Prior art keywords
- hydrogel
- estrogen
- heat
- sustained
- mixed solution
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 48
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 48
- 239000011259 mixed solution Substances 0.000 title claims abstract description 45
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 26
- 238000010172 mouse model Methods 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 229940011871 estrogen Drugs 0.000 claims abstract description 65
- 239000000262 estrogen Substances 0.000 claims abstract description 65
- 239000000017 hydrogel Substances 0.000 claims abstract description 56
- 239000000843 powder Substances 0.000 claims abstract description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 229920000728 polyester Polymers 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 238000010257 thawing Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 8
- 229960005309 estradiol Drugs 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 description 38
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 210000004696 endometrium Anatomy 0.000 description 12
- 230000002035 prolonged effect Effects 0.000 description 11
- 239000007929 subcutaneous injection Substances 0.000 description 11
- 238000010254 subcutaneous injection Methods 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 208000031513 cyst Diseases 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 3
- 210000000713 mesentery Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000000568 mesometrium Anatomy 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920000382 poly(ethylene glycol) methyl ether-block-poly(L-lactide-co-glycolide) Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811176337.2A CN109481449A (zh) | 2018-10-10 | 2018-10-10 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
| PCT/CN2019/106729 WO2020073780A1 (zh) | 2018-10-10 | 2019-09-19 | 用于子宫内膜异位症小鼠模型建立的缓释混液、制备方法以及小鼠模型建立方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH716073B1 true CH716073B1 (de) | 2023-02-28 |
Family
ID=65690242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH01157/20A CH716073B1 (de) | 2018-10-10 | 2019-09-19 | Retard-Mischlösung zur Etablierung eines Endometriose-Mausmodells und deren Herstellungsverfahren. |
Country Status (3)
| Country | Link |
|---|---|
| CN (2) | CN109481449A (zh) |
| CH (1) | CH716073B1 (zh) |
| WO (1) | WO2020073780A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481449A (zh) * | 2018-10-10 | 2019-03-19 | 浙江大学 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
| CN115651119A (zh) * | 2022-09-28 | 2023-01-31 | 四川大学华西第二医院 | 一种雌激素缓释水凝胶及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
| CA2377786A1 (en) * | 2002-03-20 | 2003-09-20 | Universite Laval | Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions |
| CN101953774B (zh) * | 2010-09-17 | 2011-11-23 | 郑州大学 | 2-甲氧基雌二醇可注射水凝胶植入剂 |
| GB201419257D0 (en) * | 2014-10-29 | 2014-12-10 | Jagotec Ag | Pharmaceutical compositions |
| CN109481449A (zh) * | 2018-10-10 | 2019-03-19 | 浙江大学 | 用于子宫内膜异位症小鼠模型建立的缓释混液及制备方法 |
-
2018
- 2018-10-10 CN CN201811176337.2A patent/CN109481449A/zh active Pending
- 2018-10-10 CN CN202210965589.3A patent/CN115316341A/zh active Pending
-
2019
- 2019-09-19 WO PCT/CN2019/106729 patent/WO2020073780A1/zh active Application Filing
- 2019-09-19 CH CH01157/20A patent/CH716073B1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020073780A1 (zh) | 2020-04-16 |
| CN115316341A (zh) | 2022-11-11 |
| CN109481449A (zh) | 2019-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Three-dimensional bioprinting of artificial ovaries by an extrusion-based method using gelatin-methacryloyl bioink | |
| Brinster | Studies on the development of mouse embryos in vitro. I. The effect of osmolarity and hydrogen ion concentration | |
| EP1250416B1 (de) | Künstlich hergestelltes, dreidimensionales Säugerherzmuskelgewebe und Herstellungsverfahren | |
| DE60206635T2 (de) | Intrauterine vorrichtung und verfahren zum einführen eines aktiven elementes in die vorrichtung | |
| Murray et al. | Demonstration of the formation of reticulin by Schwannian tumor cells in vitro | |
| DE60204352T2 (de) | Haut/haar-äquivalent mit rekonstruierten papillen | |
| DE69736911T2 (de) | Kontrazeptives Implantat für Männer | |
| CH716073B1 (de) | Retard-Mischlösung zur Etablierung eines Endometriose-Mausmodells und deren Herstellungsverfahren. | |
| DE202008018583U1 (de) | Arzneimittelgabe-Vorrichtung (Drug-Delivery-System) für die lokale Analgesie, Lokalanästhesie oder Nervenblockade | |
| JPH02276570A (ja) | 組織等価物及びその製造方法 | |
| EP1404264A2 (de) | Insert zur behandlung des trockenen auges | |
| Duncan et al. | Mitochondrial alterations in cultures of the central nervous system as observed with the electron microscope | |
| DE3104815C2 (de) | Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe | |
| DE102011011092A1 (de) | Gelierendes Kollagen und Mittel zu dessen Bereitstellung | |
| DE60133644T2 (de) | Embryonale stammzellen abkünftig aus affen | |
| Salén et al. | Exogenous collagen in the closure of tympanic membrane perforations: a preliminary report | |
| DE69105114T2 (de) | Methode zur erhöhung der fruchtbarkeit weiblicher säuger. | |
| Del Pino | Progesterone induces incubatory changes in the brooding pouch of the frog Gastrotheca riobambae (Fowler) | |
| EP2879727B1 (de) | Kit, dessen verwendung und verfahren zum auffüllen von bindegewebe der haut | |
| DE69830176T2 (de) | Arzneimittel gegen infertilität, die mit endometriose assoziiert ist | |
| CN112262818A (zh) | 上皮性卵巢癌原位成瘤小鼠模型 | |
| Huckins | The initiation of spermatogenesis in the testis of the Wistar albino rat | |
| DE3624422A1 (de) | Mittel zur beeinflussung, vor allem foerderung, der geschlechtstaetigkeit von saeugetieren und dabei insbesondere vervielfachung der geschlechtsprodukterzeugung, bezogen auf die fuer die art charakteristische lebensleistung, sowie zur gewinnung von fuer die natuerliche und die kuenstliche befruchtung geeigneten geschlechtsprodukten von saeugetieren im prae- und postnatalen leben, im infantilen alter, der vorpubertaet und im ausgewachsenen zustand (zusammenfassend ausgedrueckt: medien), sowie ihre verwendung | |
| CN107841484A (zh) | 一种体外卵母细胞培养体系及其应用 | |
| Moyer et al. | Investigations of intrauterine devices in Macaca mulatta monkeys |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PK | Correction |
Free format text: BERICHTIGUNG |
|
| PL | Patent ceased |